[1] UHRIN P, WANG D, MOCAN A, et al.Vascular smooth muscle cell proliferation as a therapeutic target. part 2: Natural products inhibiting proliferation[J]. Biotechnol Adv, 2018, 36(6):1608-1621.
[2] TESAURO M, MAURIELLO A, ROVELLA V, et al.Arterial ageing:from endothelial dysfunction to vascular calcification[J]. J Intern Med, 2017, 281(5):471-482.
[3] SHANKMAN L S, GOMEZ D, CHEREPANOVA O A, et al.KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis[J]. Nat Med, 2015, 21(6):628-637.
[4] BENNETT M R, SINHA S, OWENS G K.Vascular smooth muscle cells in atherosclerosis[J]. Circ Res, 2016, 118(4):692-702.
[5] RAMOS K S. H-RAS controls phenotypic profiles of vascular smooth muscle cells and the pathogenesis of vascular proliferative disorders[J]. Circ Res, 2009, 104(10):1139-1141.
[6] TAO R, LU L, ZHANG R, et al.Triptolide inhibits rat vascular smooth muscle cell proliferation and cell cycle progression via attenuation of ERK1/2 and Rb phosphorylation[J]. Exp Mol Pathol, 2011, 90(2):137-142.
[7] TUCKA J, YU H, GRAY K, et al. Akt1 regulates vascular smooth muscle cell apoptosis through FoxO3a and Apaf1 and protects against arterial remodeling and atherosclerosis[J].Arterioscler Thromb Vasc Biol, 2014, 34(11):2421-2428.
[8] DUAN Y, ZHANG Y, QU C, et al.CKLF1 aggravates neointimal hyperplasia by inhibiting apoptosis of vascular smooth muscle cells through PI3K/AKT/NF-κB signaling[J]. Biomed Pharmacother, 2019, 117:108986.
[9] CHE H L, BAE I H, LIM K S, et al.Therapeutic effect of akt1 sirna nanoparticle eluting coronary stent on suppression of post-angioplasty restenosis[J]. J Biomed Nanotechnol, 2016, 12(6):1211-1122.
[10] CAGLAYAN E, VANTLER M, LEPPäNEN O, et al.Disruption of platelet-derived growth factor-dependent phosphatidylinositol 3-kinase and phospholipase Cγ 1 activity abolishes vascular smooth muscle cell proliferation and migration and attenuates neointima formation in vivo[J]. J Am Coll Cardiol, 2011, 57(25):2527-2538.
[11] XIANG S, DONG N G, LIU J P, et al. Inhibitory effects of suppressor of cytokine signaling 3 on inflammatory cytokine expression and migration and proliferation of IL-6/IFN-γ-induced vascular smooth muscle cells[J]. J Huazhong Univ Sci Technol Med Sci, 2013, 33(5):615-622.
[12] PERSSON C, ENGSTRÖM U, MOWBRAY S L, et al. Primary sequence determinants responsible for site-selective dephosphorylation of the PDGF beta-receptor by the receptor-like protein tyrosine phosphatase DEP-1[J]. FEBS Lett, 2002, 517(1/3):27-31.
[13] DAHAL B K, CORNITESCU T, TRETYN A, et al. Role of epidermal growth factor inhibition in experimental pulmonary hypertension[J]. Am J Respir Crit Care Med, 2010, 181(2):158-167.
[14] HU Q, CHEN J, ZHANG J, et al. IOX1, a JMJD2A inhibitor, suppresses the proliferation and migration of vascular smooth muscle cells induced by angiotensin II by regulating the expression of cell cycle-related proteins[J]. Int J Mol Med, 2016, 37(1):189-196.
[15] HARITH H H, DI BARTOLO B A,CARTLAND S P, et al.Insulin promotes vascular smooth muscle cell proliferation and apoptosis via differential regulation of tumor necrosis factor-related apoptosis-inducing ligand[J]. J Diabetes, 2016, 8(4):568-578.
[16] MARX S O, TOTARY-JAIN H, MARKS A R, et al.Vascular smooth muscle cell proliferation in restenosis [J]. Circ Cardiovasc Interv, 2011, 4(1): 104-111.
[17] LIU X, CHENG Y, ZHANG S, et al.A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia[J]. Circ Res, 2009, 104(4): 476-487.
[18] YANG F, CHEN Q, HE S, et al. miR-22 is a novel mediator of vascular smooth muscle cell phenotypic modulation and neointima formation[J]. Circulation, 2018, 137(17): 1824-1841.
[19] YANG X, SONG J H, CHENG Y, et al.Long non-coding RNA HNF1A-AS1 regulates proliferation and migration in oesophageal adenocarcinoma cells[J]. Gut, 2014, 63(6): 881-890.
[20] LIU Y, CUI X, WANG C, et al.LncRNA HCG11 regulates proliferation and apoptosis of vascular smooth muscle cell through targeting miR-144-3p/FOXF1 axis in atherosclerosis[J]. Biol Res, 2020, 53(1):44.
[21] SHI X, WEI Y T, LI H, et al.Long non-coding RNA H19 in atherosclerosis: what role? [J]. Mol Med, 2020, 26(1): 72.
[22] ZHU L, CHEN L.Progress in research on paclitaxel and tumor immunotherapy[J]. Cell Mol Biol Lett, 2019, 24:40.
[23] ALFONSO F, PEREZ-VIZCAYNO M J, CUESTA J, et al.Paclitaxel-eluting balloons or everolimus-eluting stents for in-stent restenosis[J]. JACC Cardiovasc Interv, 2018, 11(5):505-506.
[24] BENJAMIN D, COLOMBI M, MORONI C, et al. Rapamycin passes the torch: a new generation of mTOR inhibitors[J]. Nat Rev Drug Discov, 2011, 10(11): 868-880.
[25] KOBO O, A ROGUIN. Orsiro: ultrathin bioabsorbable polymer sirolimus-eluting stent[J]. Future Cardiol, 2019, 15(4):295-300.
[26] ZHANG Z, ZHANG D, DU B, et al. Hyperoside inhibits the effects induced by oxidized low-density lipoprotein in vascular smooth muscle cells via oxLDL-LOX-1-ERK pathway[J]. Mol Cell Biochem, 2017, 433(1/2):169-176.
[27] CHEN Z, PAN X, SHENG Z, et al. Baicalin suppresses the proliferation and migration of Ox-LDL-VSMCs in atherosclerosis through upregulating miR-126-5p[J]. Biol Pharm Bull, 2019, 42(9):1517-1523. |
